Addiction clinics are reporting a surge in patients dependent on potent kratom products — and increasingly severe withdrawal — as a highly concentrated compound reshapes what was once marketed as a mild herbal supplement into something that behaves much more like an opioid.

What’s driving it: 7-OH

The culprit is 7-hydroxymitragynine (7-OH). It occurs only in trace amounts in the natural kratom leaf, but newer commercial products contain it in highly concentrated form. That matters because 7-OH acts directly on the brain’s opioid receptors, producing stronger, more opioid-like effects — sedation and euphoria — and, with them, a real potential for dependence and difficult withdrawal. In effect, concentrating this one compound turns a plant product into a potent opioid-like drug.

The numbers clinics are seeing

The trend shows up starkly in clinic data. At the telehealth addiction provider Boulder Care, patients reporting kratom use rose from 3% of new patients in September 2025 to 8% by July 2026, then jumped to 14% in August. Two inpatient clinics run by Recovery Centers of America in Massachusetts now see roughly 10 to 20 people a week who are either fully dependent on kratom or 7-OH, or for whom those products are part of a broader substance-use problem.

The regulatory response

Authorities have started to act. In July 2026, the DEA announced temporary Schedule I control of 7-OH and several related synthetic compounds, while distinguishing natural botanical kratom from these synthesized or highly concentrated substances — an important line, since much of the concern centers on the concentrated products rather than the traditional leaf. That same month, the FDA sent warning letters to seven companies marketing 7-OH products.

The treatment challenge

Clinicians are somewhat in uncharted territory. There is no FDA-approved protocol specifically for 7-OH dependence. The best-documented options in published case reports are the opioid-use-disorder medications buprenorphine and buprenorphine-naloxone — which makes sense given 7-OH’s opioid-like action — with one 2025 case series reporting successful stabilization in nearly 89% of cases. Still, evidence remains thin, and standardized guidance is lacking.

Why it matters

This is a case study in how a lightly regulated market can outpace both science and policy. Kratom has long occupied a gray zone — used by some people to manage pain or to reduce opioid use — but the rise of concentrated 7-OH products has changed the risk profile substantially, without most consumers necessarily realizing it. The practical message: products labeled “kratom” are not all the same, and concentrated 7-OH can cause genuine opioid-like dependence. Anyone struggling with kratom or 7-OH withdrawal should know that help exists — including established addiction medications — and is worth seeking. This summarizes public-health reporting and is not medical advice; seek care for substance-use concerns.